Singh J, Reddy B
Int J Oncol. 1995 Feb;6(2):301-6.
Accumulating data suggest that activation of ms proto-oncogenes and inactivation of tumor suppressor genes induce malignant phenotype in colonic cells. However, the transforming ability of ras oncogenes critically depends on correct localization of ras-p21 in plasma membrane. In our previous studies, we demonstrated a strong correlation between the modulation of ras activation (both in terms of mutational activation and over-expression of ras genes) by chemopreventive agents and colon tumor outcome during different stages of azoxymethane (AOM)-induced colon carcinogenesis. In the present study, which is a part of our ongoing investigations on the role of ras in chemoprevention of colon cancer, we studied the effect of D,L-alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal antiinflammatory drug (NSAID), on the post-translational membrane association of ras-p21 during AOM-induced colon carcinogenesis. Groups of male F344 rats were fed the modified AIN-76A diets containing 0, 150 ppm piroxicam or 4000 ppm DFMO, and administered s.c. AOM dissolved in normal saline at a dose rate of 15 mg/kg body weight/week for 4 weeks. Vehicle control groups received equal volume of normal saline. Groups of animals were then sacrificed at 4, 16, 24, and 32 weeks after last AOM or saline injection and their colonic mucosa and tumors were analyzed for cytoplasmic as well as membrane bound ras-p21 levels. AOM-treatment resulted in increasingly higher levels of membrane-bound ras-p21 with advancing stages of colon tumorigenesis without any significant changes in cytoplasmic ras-p21. Dietary DFMO significantly suppressed AOM-induced membrane-bound ras-p21 in a time-dependent manner. Administration of piroxicam though resulted in significant inhibition of membrane-bound ras-p21, but concomitantly increased the cytosolic levels of ras-p21. Inhibition of membrane-bound ras-p21 levels by DFMO and piroxicam strongly correlated with the suppression of AOM-induced colon tumorigenesis by these agents. Data from the present and earlier studies suggest that DFMO may afford chemoprevention by suppressing DNA and protein biosynthesis by depleting intracellular polyamines, whereas piroxicam may exert its antitumor activity by interfering with post-translational membrane localization of ras-p21, in addition to modulating arachidonic acid metabolism.
越来越多的数据表明,原癌基因的激活和抑癌基因的失活会诱导结肠细胞出现恶性表型。然而,ras癌基因的转化能力关键取决于ras-p21在质膜中的正确定位。在我们之前的研究中,我们证明了化学预防剂对ras激活的调节(包括ras基因的突变激活和过表达)与偶氮甲烷(AOM)诱导的结肠癌不同阶段的结肠肿瘤结局之间存在密切关联。在本研究中,作为我们正在进行的关于ras在结肠癌化学预防中作用的调查的一部分,我们研究了鸟氨酸脱羧酶不可逆抑制剂D,L-α-二氟甲基鸟氨酸(DFMO)和非甾体抗炎药(NSAID)吡罗昔康在AOM诱导的结肠癌发生过程中对ras-p21翻译后膜结合的影响。将雄性F344大鼠分为几组,分别喂食含0、150 ppm吡罗昔康或4000 ppm DFMO的改良AIN-76A饮食,并以15 mg/kg体重/周的剂量皮下注射溶解于生理盐水中的AOM,持续4周。溶剂对照组接受等量的生理盐水。然后在最后一次注射AOM或生理盐水后的4、16、24和32周处死动物组,分析其结肠黏膜和肿瘤中细胞质以及膜结合的ras-p21水平。AOM处理导致随着结肠肿瘤发生阶段的推进,膜结合的ras-p21水平越来越高,而细胞质中的ras-p21没有任何显著变化。饮食中的DFMO以时间依赖性方式显著抑制AOM诱导的膜结合ras-p21。虽然吡罗昔康的给药导致膜结合ras-p21的显著抑制,但同时增加了ras-p21的胞质水平。DFMO和吡罗昔康对膜结合ras-p21水平的抑制与这些药物对AOM诱导的结肠肿瘤发生的抑制密切相关。本研究和早期研究的数据表明,DFMO可能通过耗尽细胞内多胺来抑制DNA和蛋白质生物合成从而提供化学预防作用,而吡罗昔康除了调节花生四烯酸代谢外,还可能通过干扰ras-p21的翻译后膜定位发挥其抗肿瘤活性。